Literature DB >> 23529040

Increased fracture risk with HIV infection--a growing concern.

Roger Bedimo, Pablo Tebas.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23529040     DOI： 10.1038/nrendo.2013.62

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

Authors:  Roger Bedimo; Naim M Maalouf; Song Zhang; Henning Drechsler; Pablo Tebas
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

2.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.

Authors:  P Tebas; W G Powderly; S Claxton; D Marin; W Tantisiriwat; S L Teitelbaum; K E Yarasheski
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

3.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

Authors:  Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

4.  Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.

Authors:  Jennifer Hoy; Birgit Grund; Mollie Roediger; Kristine E Ensrud; Indira Brar; Robert Colebunders; Nathalie De Castro; Margaret Johnson; Anjali Sharma; Andrew Carr
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

Review 5.  Bone disease in HIV infection: a practical review and recommendations for HIV care providers.

Authors:  Grace A McComsey; Pablo Tebas; Elizabeth Shane; Michael T Yin; E Turner Overton; Jeannie S Huang; Grace M Aldrovandi; Sandra W Cardoso; Jorge L Santana; Todd T Brown
Journal:  Clin Infect Dis       Date:  2010-10-15       Impact factor: 9.079

6.  Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study.

Authors:  S Serrano; M L Mariñoso; J C Soriano; J Rubiés-Prat; J Aubia; J Coll; J Bosch; L Del Rio; J Vila; A Goday
Journal:  Bone       Date:  1995-02       Impact factor: 4.398

7.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

8.  Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system.

Authors:  Virginia A Triant; Todd T Brown; Hang Lee; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2008-07-01       Impact factor: 5.958

9.  HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study.

Authors:  Robert Güerri-Fernandez; Peter Vestergaard; Cristina Carbonell; Hernando Knobel; Francesc Fina Avilés; Alberto Soria Castro; Xavier Nogués; Daniel Prieto-Alhambra; Adolfo Diez-Perez
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741
  9 in total
  1 in total

1.  Comparison of peripheral forearm DXA and clinical risk factor screening using FRAX® to assess the risk of HIV-associated low bone mass: a cross-sectional study.

Authors:  Charlotte-Eve S Short; Simon G Shaw; Martin J Fisher; Yvonne C Gilleece; Karen Walker-Bone
Journal:  Arch Osteoporos       Date:  2014-05-14       Impact factor: 2.617
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.